Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.

Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S.

Oncotarget. 2019 Sep 3;10(51):5383-5384. doi: 10.18632/oncotarget.27175. eCollection 2019 Sep 3.

2.

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.

Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S.

Oncotarget. 2017 May 9;8(19):31478-31493. doi: 10.18632/oncotarget.15649. Erratum in: Oncotarget. 2019 Sep 03;10(51):5383-5384.

3.

Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?

Eyre TA.

Oncotarget. 2019 Feb 26;10(17):1661. doi: 10.18632/oncotarget.26767. eCollection 2019 Feb 26.

4.

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2019 Aug 20;10(49):5120-5122. doi: 10.18632/oncotarget.27162. eCollection 2019 Aug 20.

6.

Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition.

Khan AE, Gallo V, Linseisen J, Kaaks R, Rohrmann S, Raaschou-Nielsen O, Tjønneland A, Johnsen HE, Overvad K, Bergmann MM, Boeing H, Benetou V, Psaltopoulou T, Trichopoulou A, Masala G, Mattiello A, Grioni S, Tumino R, Vermeulen RC, Peeters PH, Bueno-de-Mesquita HB, Ros MM, Lund E, Ardanaz E, Chirlaque MD, Jakszyn P, Larrañaga N, Losada A, Becker N, Nieters A, Martínez-García C, Agren A, Hallmans G, Berglund G, Manjer J, Allen NE, Key TJ, Bingham S, Khaw KT, Slimani N, Ferrari P, Boffetta P, Norat T, Vineis P, Riboli E; EPIC Group.

Haematologica. 2008 Jun;93(6):842-50. doi: 10.3324/haematol.12297. Epub 2008 Apr 28.

7.

Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.

Li ZM, Jiang WQ, Zhu ZY, Zhu XF, Zhou JM, Liu ZC, Yang DJ, Guang ZZ.

Cancer Biol Ther. 2008 Jan;7(1):51-60. Epub 2007 Oct 8.

PMID:
17938578
8.

Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment.

Liu L, Zhang M, Zou P.

Oncology. 2008;74(1-2):96-103. doi: 10.1159/000139137. Epub 2008 Jun 12.

PMID:
18547964
9.

Is fascin really a useful marker in distinguishing between classical Hodgkin's lymphoma and various types of non-Hodgkin's lymphomas in difficult cases?

Idrees R, Ahmad Z, Qureshi A, Ahsan A, Pervez S.

J Clin Pathol. 2010 Jul;63(7):571-4. doi: 10.1136/jcp.2009.075127.

PMID:
20591908
10.

Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease.

Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS.

N Engl J Med. 1979 Mar 1;300(9):452-8.

PMID:
366418
11.

Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.

Bräuninger A, Hansmann ML, Strickler JG, Dummer R, Burg G, Rajewsky K, Küppers R.

N Engl J Med. 1999 Apr 22;340(16):1239-47.

12.

Correlation between apoptosis, proliferation and bcl-2 expression in malignant non-Hodgkin's lymphoma.

Kiberu SW, Pringle JH, Sobolewski S, Murphy P, Lauder I.

Clin Mol Pathol. 1996 Oct;49(5):M268-72.

13.

Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.

Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, Uyttebroeck A, Bechter O, Delforge M, Vandecaveye V, Brison N, Verhoef GE, Legius E, Amant F, Vermeesch JR.

Lancet Haematol. 2015 Feb;2(2):e55-65. doi: 10.1016/S2352-3026(14)00039-8. Epub 2015 Jan 20.

PMID:
26687610
14.

Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma.

Botchan A, Hauser R, Gamzu R, Yogev L, Lessing JB, Paz G, Yavetz H.

Hum Reprod. 1997 Jan;12(1):73-6.

PMID:
9043906
15.
16.

Coping with non-Hodgkin's lymphoma: a qualitative study of patient perceptions and supportive care needs whilst undergoing chemotherapy.

Chircop D, Scerri J.

Support Care Cancer. 2017 Aug;25(8):2429-2435. doi: 10.1007/s00520-017-3649-0. Epub 2017 Feb 23.

PMID:
28233120
17.

[Hodgkin's disease and non-Hodgkin's lymphoma occurring simultaneously].

Bosch F, Ordi J, López-Guillermo A, Campo E, Montserrat E, Rozman C.

Med Clin (Barc). 1993 May 22;100(20):788-90. Spanish.

PMID:
8321056
18.
19.

Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.

Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, von Strandmann EP.

Clin Cancer Res. 2009 Aug 15;15(16):5108-16. doi: 10.1158/1078-0432.CCR-09-0213. Epub 2009 Aug 11.

20.

Head and neck manifestations of non-Hodgkin's lymphoma in human immunodeficiency virus-infected patients.

Singh B, Poluri A, Shaha AR, Michuart P, Har-El G, Lucente FE.

Am J Otolaryngol. 2000 Jan-Feb;21(1):10-3.

PMID:
10668671

Supplemental Content

Support Center